Viriathus Research LLC, an independent research firm, issued an Overview Report today on Fibrocell Science, Inc., (OTCBB: FCSC), an aesthetic and therapeutic development stage biotechnology company focused on developing and commercializing novel skin and tissue rejuvenation products utilizing the Company's proprietary Fibrocell Therapy technology platform.
The report provides a description of Fibrocell's business, industry, product, strategy, management team, and investment opportunities and risks.
If you would like a complimentary copy of this report, please email david.boral@viriathus.com
About Viriathus Research LLC
Viriathus Research is a quality-leading New York based independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutions that invest in them.
For further information on Viriathus Research, please visit www.viriathus.com/Research.htm
About Fibrocell Science, Inc.
Fibrocell is an aesthetic and therapeutic development stage biotechnology company focused on developing and commercializing novel skin and tissue rejuvenation products utilizing the Company's proprietary Fibrocell Therapy technology platform. Fibrocell Therapy is a patented process to extract, purify, multiply and re-inject a patient's own natural fibroblast cells as a personalized therapy. Its' most advanced indication is for the treatment of nasolabial folds (lines running along the sides of the nose to the corner of the mouth) and wrinkles, based on its patented autologous cellular therapy. Fibrocell's technology uses the patient's own fibroblast cells, which are harvested and multiplied in its Exton, PA laboratory, then processed into an injectable that provides dermal repair and rejuvenation. The Company's technology has broad potential applications in the treatment of wrinkles, acne scars, restrictive burn scars and dental soft tissue regeneration. Fibrocell anticipates being first to market with an all-natural, minimally invasive cellular therapy which carries none of the risks of ablative or other injectable treatments.
For further information on Fibrocell Science, Inc., please visit www.fibrocellscience.com.
Statement under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.
Viriathus Research has issued this report on Fibrocell Science, Inc., and has been compensated $25,000.00.
Contacts:
Viriathus Research LLC
Lisa Springer, +1 212-461-2230
lisa.springer@viriathus.com
www.viriathus.com